NCT03106818

Brief Summary

Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 4, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 10, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

November 22, 2017

Status Verified

November 1, 2017

Enrollment Period

8 months

First QC Date

April 4, 2017

Last Update Submit

November 21, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative pain

    Vas Scale

    48 hours postoperative

Secondary Outcomes (2)

  • extubation time

    48 hours

  • Fentanyl consumption

    48 hours

Study Arms (3)

group A

ACTIVE COMPARATOR

( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours

Drug: bupivacain with magnesium sulphate

group B

ACTIVE COMPARATOR

bupivacaine 0.125% infusion in the presternum , for 48 hours

Drug: Bupivacaine only

Group C

ACTIVE COMPARATOR

will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.

Drug: conventional

Interventions

will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours

Also known as: local anesthetic with adjuvant for 48 hours
group A

will receive bupivacain 0.125% infusion in the presternum , for 48 hours

Also known as: local anesthetic
group B

only conventional post operative analgesics will be used

Also known as: paracetamol , Ketorolac
Group C

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • years old
  • American Society of Anesthesiologists physical status II and III
  • Patients scheduled for open heart valve replacement surgery with sternotomy

You may not qualify if:

  • Emergency surgery
  • Clinically significant kidney or liver disease
  • Patients allergic to local anesthetic
  • Patients with prolonged CPB time (\>120 min)
  • Patients required intra-aortic balloon pump

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emad Zarief Kamel Said

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Magnesium SulfateAnesthetics, LocalAdjuvants, PharmaceuticCongresses as TopicAcetaminophenKetorolac

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Magnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsAnestheticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic UsesPharmaceutic AidsPharmaceutical PreparationsSpecialty Uses of ChemicalsOrganizationsHealth Care Economics and OrganizationsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesIndomethacinIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Emad Kamel Said, MD

    Anesthesia departement , Faculty of Medicine , Assiut university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: pain control in the early postoperative period
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia and ICU

Study Record Dates

First Submitted

April 4, 2017

First Posted

April 10, 2017

Study Start

July 1, 2016

Primary Completion

March 1, 2017

Study Completion

July 1, 2017

Last Updated

November 22, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share

Locations